ALL, HL guidelines added to radiation therapy resource

Therapist preparing patient
to receive radiation
Photo by Rhoda Baer
The National Comprehensive Cancer Network® (NCCN) has added 9 disease sites to its NCCN Radiation Therapy Compendium™, a resource that provides a single access point for NCCN recommendations pertaining to radiation therapy (RT). The compendium provides guidance on all RT modalities recommended within... [Read Article]

CHMP recommends drug for relapsed/refractory cHL

Pembrolizumab (Keytruda)
Photo courtesy of Merck
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the anti-PD-1 therapy pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The recommendation pertains specifically to adults with cHL who have... [Read Article]

Most blood cancer mutations due to DNA replication errors

DNA helices
Image courtesy of the
National Institute of
General Medical Sciences
A new study supports the idea that most cancer-driving mutations are a result of DNA replication errors, not heredity or lifestyle/environmental factors. For all 32 cancer types studied, researchers found that 66% of driver mutations resulted from DNA replication errors,... [Read Article]